Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #6632 on Arbutus Biopharma Corporation (ABUS)
mick
02/05/23 6:57 PM
#6634 RE: DewDiligence #6632
DewDiligence
03/02/23 9:08 AM
#6638 RE: DewDiligence #6632
We have nominated, AB-343 as our lead coronavirus drug candidate that inhibits the main protease (Mpro). In pre-clinical research conducted thus far, AB-343 has shown pan-coronavirus antiviral activity, no reduction in potency against known SARS-CoV-2 variants, robust activity against SARS-CoV-2 Mpro resistant strains, and a favorable drug-drug interaction profile with no need for ritonavir boosting. We expect to complete IND-enabling studies and initiate a Phase 1 clinical trial with AB-343 in the second half of 2023.